

CORRELATION ANALYSIS OF SERUM NT-PRO-BNP, IGFBP-7 AND CTRP12 LEVELS IN CHRONIC HEART FAILURE PATIENTS

KORELACIJA NIVOVA SERUMSKOG NT-PRO-BNP, IGFBP-7 I CTRP12 KOD PACIJENATA SA HRONIČNOM SRČANOM INSUFICIJENCIJOM

Zhen Fan¹, Heng Huang², Laoji Wang³, Jierou Yan³, Fei Zhao⁴

¹Department of Cardiology, The Affiliated Chuzhou Hospital of Anhui Medical University (The First People's Hospital of Chuzhou), No. 369, Zuiweng West Road, Nanqiao District, Chuzhou City 239000, China

²Department of Laboratory Medicine, Western Theatre Command Air Force Hospital, No. 1, Gongnongyuan Street, Jinjiang District, Chengdu City 610065, China

³Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei City 230000, China

⁴Department of Cardiology, The First People's Hospital of Xiaoshan District, Hangzhou, No. 199, Shixin South Road, Xiaoshan District, Hangzhou City 311200, China

Summary

Background: To investigate serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP), insulin-like growth factor binding protein-7 (IGFBP-7), and C1q tumour necrosis factor-related protein 12 (CTRP12) levels and significance in patients with chronic heart failure (CHF).

Methods: The CHF group consisted of 116 CHF patients who received care at this hospital between October 2023 and March 2025. The patients were classified into Grade II (47 patients), Grade III (41 patients), or Grade IV (28 patients) based on the heart function classification of the New York Heart Association (NYHA). The control group consisted of 64 healthy patients who were physically examined in the hospital during the same period. Using multivariate logistic regression, the factors impacting MACEs in patients with congestive heart failure were examined. Through the use of the receiver operating characteristic (ROC) curve, researchers were able to assess the predictive power of blood NT-pro-BNP, IGFBP-7, and CTRP12 for MACEs in chronic heart failure patients.

Results: Comparing the CHF group to the control group, the LVEDD increased, the LVEF and serum CTRP12 decreased, and the levels of NT-pro-BNP, IGFBP-7, Hcy, and hs-CRP climbed ($P < 0.05$). Among patients with CHF

Kratak sadržaj

Uvod: Cilj je bio da se ispituju nivoi i značaj serumskog N-terminalnog pro-peptida moždanog natriuretičkog hormona (NT-pro-BNP), proteina vezanog za insulinu sličan faktor rasta 7 (IGFBP-7) i C1q proteina povezanog sa faktorom nekroze tumora 12 (CTRP12) kod pacijenata sa hroničnom srčanom insuficijencijom (CHF).

Metode: Grupa CHF obuhvatila je 116 pacijenata sa hroničnom srčanom insuficijencijom koji su lečeni u ovoj bolnici u periodu od oktobra 2023. do marta 2025. Pacijenti su klasifikovani kao »Grade« II (47 pacijenata), »Grade« III (41 pacijent), ili »Grade« IV (28 pacijenata) na osnovu klasifikacije srčane funkcije prema »New York Heart Association« (NYHA). Kontrolna grupa činilo je 64 zdrava pacijenta koji su u istom periodu obavljali preventivne preglede u bolnici. Korišćenjem multivarijatne logističke regresije analizirani su faktori koji utiču na pojavu glavnih kardiovaskularnih neželjenih događaja (MACE) kod pacijenata sa kongestivnom srčanom insuficijencijom. Kroz korišćenje ROC krive procenjena je prediktivna vrednost nivoa NT-pro-BNP, IGFBP-7 i CTRP12 u serumu za MACE kod pacijenata sa CHF.

Rezultati: U poređenju sa kontrolnom grupom, kod CHF grupe došlo je do povećanja LVEDD, smanjenja LVEF i serumskog CTRP12, dok su nivoi NT-pro-BNP, IGFBP-7,

Address for correspondence:

Fei Zhao
Department of Cardiology, The First People's Hospital of Xiaoshan District, Hangzhou
No. 199, Shixin South Road, Xiaoshan District,
Hangzhou City 311200, China
e-mail: wzmcfz@163.com

of different grades, serum NT-pro-BNP, IGFBP-7, Hcy, hs-CRP, and LVEDD levels were all lower in Grade II patients than in Grade III patients. Furthermore, the differences between any two grades were statistically significant ($P < 0.05$). The levels of LVEF and serum CTRP12 in the MACE group decreased, the LVEDD increased, and the levels of serum Hcy, hs-CRP, NT-pro-BNP and IGFBP-7 increased ($P < 0.05$). MACEs in CHF patients were influenced by serum NT-pro-BNP, IGFBP-7, and CTRP12 ($P < 0.05$). The areas under the curve (AUCs) of serum NT-pro-BNP, IGFBP-7, CTRP12 alone and the combination of the three for predicting MACEs in patients with CHF were 0.862 (95% CI: 0.786–0.919), 0.805 (95% CI: 0.721–0.872), and 0.860 (95% CI: 0.784–0.918) and 0.961 (95% CI: 0.908–0.988), respectively. The AUCs of the three combined predictions were significantly greater than those of the individual predictions of NT-pro-BNP, IGFBP-7, and CTRP12 ($Z = 3.050, 3.883, 3.218$, all $P < 0.05$).

Conclusions: Serum levels of IGFBP-7 and NT-pro-BNP increase in CHF patients, whereas the level of CTRP12 decreases. Additionally, once functional classification was applied, NT-pro-BNP, IGFBP-7, and CTRP12 levels changed. The combined detection of these three parameters has better efficacy in predicting MACEs in patients with CHF.

Keywords: C1q tumour necrosis factor-related protein 12, chronic heart failure, IGFBP-7, NT-pro-BNP

Introduction

The advanced symptom of many cardiovascular disorders is chronic heart failure (CHF) (1). Its main clinical features include symptoms such as shortness of breath, oedema, reduced exercise tolerance, and fatigue. If not treated in time, it can easily lead to adverse events such as cardiogenic lung disease, cardiogenic shock, and even sudden death (2). Therefore, finding biological indicators that can accurately diagnose and assess patient prognosis is significant (3). It is synthesised mainly by myocardial cells in the body and is decomposed under the action of proteolytic enzymes. Studies (4–6) have shown that NT-pro-BNP is involved in and affects the occurrence and progression of CHF. Insulin-like growth factor binding protein-7 (IGFBP-7) is a soluble secretory glycoprotein that is widely expressed in various tissues of the body and regulates a series of physiological processes, such as cell growth and adhesion, proliferation, apoptosis and angiogenesis. Studies (7–9) have shown that IGFBP-7 is involved in the occurrence of many cardiovascular diseases. C1q tumour necrosis factor-related protein 12 (CTRP12) is a member of the CTRP family and is highly homologous to adiponectin. It participates in and influences the occurrence and development of related diseases, such as diabetes, insulin resistance, and cardiovascular diseases (10, 11). Accurate assessment of the severity of the disease, early identification of high-risk patients and individualised management are the keys to improving patient prognosis. Currently, a traditional biomarker is crucial for the diagnosis and prognosis assessment of CHF

Hcy i hs-CRP porasli ($P < 0,05$). Kod pacijenata sa CHF različitih stepena, nivoi serumskog NT-pro-BNP, IGFBP-7, Hcy, hs-CRP i LVEDD bili su niži kod pacijenata »Grade« II u odnosu na »Grade« III, a razlike između bilo koja dva stepena bile su statistički značajne ($P < 0,05$). Nivoi LVEF i serumskog CTRP12 u MACE grupi su se smanjili, LVEDD je porastao, a nivoi serumskog Hcy, hs-CRP, NT-pro-BNP i IGFBP-7 su se povećali ($P < 0,05$). MACE kod pacijenata sa CHF bili su pod uticajem serumskih nivoa NT-pro-BNP, IGFBP-7 i CTRP12 ($P < 0,05$). Površine ispod krive (AUC) za predikciju MACE kod pacijenata sa CHF bile su: NT-pro-BNP – 0,862 (95% CI: 0,786–0,919), IGFBP-7 – 0,805 (95% CI: 0,721–0,872), CTRP12 – 0,860 (95% CI: 0,784–0,918), dok je kombinacija sva tri parametra dala AUC 0,961 (95% CI: 0,908–0,988). AUC kombinovane predikcije su bila značajno veće od pojedinačnih predikcija NT-pro-BNP, IGFBP-7 i CTRP12 ($Z = 3,050; 3,883; 3,218$, svi $P < 0,05$).

Zaključak: Serumski nivoi IGFBP-7 i NT-pro-BNP su povećani kod pacijenata sa CHF, dok je nivo CTRP12 smanjen. Takođe, nakon primene funkcionalne klasifikacije, nivoi NT-pro-BNP, IGFBP-7 i CTRP12 su se menjali. Kombinovana detekcija ova tri parametra ima veću efikasnost u predviđanju MACE kod pacijenata sa CHF.

Ključne reči: C1q protein povezan sa faktorom nekroze tumora 12, hronična srčana insuficijencija, IGFBP-7, NT-pro-BNP

(12). However, its level is affected by multiple factors, and a single indicator has limitations (13). Insulin-like growth factor binding protein 7 (IGFBP-7) is closely related to myocardial fibrosis and the inflammatory response and is considered a potential indicator of myocardial remodelling and cardiac dysfunction. C1q/tumour necrosis factor-related protein 12 (CTRP12), an adipokine with anti-inflammatory and metabolic regulatory effects, has increasingly drawn attention for its connection with cardiovascular protection and energy metabolism. However, studies (14–16) on the expression characteristics of serum IGFBP-7 and CTRP12 in patients with CHF and their intrinsic associations with NT-pro-BNP are still insufficient (17). Therefore, this study aims to explore the correlations among NT-pro-BNP, IGFBP-7, and CTRP12 levels in the serum of patients and their association with disease severity. By jointly detecting these levels, the study seeks to reveal their synergistic mechanism and clinical value in the disease process. Our study provides a new scientific basis and diverse assessment perspectives for risk stratification, pathophysiological mechanism exploration and identification of potential therapeutic targets for CHF.

Materials and Methods

Research subjects

One hundred sixteen CHF patients, with a body mass index (BMI) of 25.18 ± 2.16 kg/m², treated at our hospital between October 2023 and March

2025, were chosen as the CHF group. Sixty-two male patients and 54 female patients were included. Forty-eight patients had coronary heart disease, 36 had hypertension, and 31 had diabetes. All patients were classified into Grade II (47 patients), Grade III (41 patients), or Grade IV (28 patients). Another 64 healthy individuals, with a BMI of 25.16 ± 2.14 kg/m². The age ranged from 45 to 86 years, with an average of 66.63 ± 18.59 years. There were 38 male patients and 26 female patients.

Inclusion criteria: (1) met the necessary diagnostic standards outlined in the »Guidelines for the Diagnosis and Treatment of Chronic Heart Failure« and had a history of heart disease symptoms; (2) Had symptoms such as edema, fatigue and shortness of breath lasting for more than half a year; (3) Had a significant decrease in exercise endurance; (4) had an ultrasonography electrocardiogram that showed heart failure symptoms, altered myocardial contractile and diastolic functions, and alterations in the left ventricle's structure and function.

Exclusion criteria: (1) Acute myocardial infarction or severe arrhythmia; (2) Severe liver or kidney dysfunction; (3) Percutaneous coronary intervention surgery one month before admission or acute myocardial infarction, unstable angina pectoris or cerebrovascular accidents within one month; (4) Accompanying haematological diseases; (5) Accompanying malignant tumours and other related diseases.

Our hospital's Medical Ethics Committee [HKYS-2025-A0224] gave its approval for this investigation. Every participant signed the informed consent form after their families explained the study to them.

Echocardiography examination

The patients' end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and those of healthy individuals were measured and recorded on the day of physical examination using the EPIQ 7C ultrasound diagnostic system (Philips, Netherlands).

Serum-related index detection

On the second day of admission, four to six millilitres of fasting venous blood were drawn from CHF patients and from the control group in the early morning. The serum was obtained after centrifugation. Homocysteine (Hcy) and hypersensitive C-reactive protein (hs-CRP) levels were measured using a BS-600 M biochemical analyser (Shenzhen Mindray Biomedical Electronics Co., Ltd.), and the level of NT-pro-BNP was detected via a Cobas e601 electrochemiluminescence analyser (Roche, Switzerland). The levels of IGFBP-7 (a kit purchased from Shanghai Zhenke Biotechnology Co., Ltd.) and CTRP12 (a kit

purchased from Xiamen Lun Changshuo Biotechnology Co., Ltd.) were determined via enzyme-linked immunosorbent assay. All laboratory indicators were tested by three skilled doctors from the hospital's laboratory department.

Laboratory testing methods and reagents

Testing methods

Enzyme-Linked Immunosorbent Assay was adopted. ELISA technology was used to detect the concentrations of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), insulin-like growth factor binding protein 7 (IGFBP-7), and C1q/ tumour necrosis factor-related protein 12 (CTRP12) in serum samples of patients with chronic heart failure. After adding the serum sample to be tested, the target antigen (NT-pro-BNP, IGFBP-7 or CTRP12) is captured by the coated antibody. Wash the plate to remove unbound substances. Then add biotin-labelled specific detection antibodies to form a »capture antibody – antigen – detection antibody« complex. After washing the plate, add Streptavidin labelled with horseradish peroxidase (HRP) to bind with biotin. Rewash the plate to remove unbound substances. Finally, the tetramethylbenzidine (TMB) substrate solution is added for the colour development reaction.

Testing reagents and apparatus

(1) NT-pro-BNP detection was conducted using the human NT-pro-BNP ELISA kit (Catalogue number: SEA479Hu) provided by Cloud-Clone Corp., Wuhan, China.

(2) IGFBP-7 detection, the Elabscience® brand Human IGFBP-7 ELISA kit (Catalogue number: E-EL-H0010; Elabscience Biotechnology Inc., an American research and development company) is selected, located in Houston, TX, USA.

(3) CTRP12 detection, the human CTRP12 ELISA kit (product number: CB-EL027015HU) produced by Wuhan Huamei Bioengineering Co., LTD. (CUSABIO).

(4) The absorbance (OD value) of each well was determined at a wavelength of 450nm using the Multiskan FC microplate reader from Thermo Fisher Scientific (Waltham, MA, USA) (item No. 51119000CN).

(5) Separation using an Eppendorf (Hamburg, Germany) Centrifuge (model Centrifuge 5810 R) at 3000 revolutions per separation center for 10 minutes.

(6) Store samples using the Thermo Scientific™ Forma™ series -80 °C ultra-low temperature refrigerator (Item No. 885003003).

Table III Comparison of general information, cardiac function indicators and serum levels of NT-pro-BNP, IGFBP-7, CTRP12, Hcy and hs-CRP between the MACE group and the non-MACE group.

Group	n	Male/Female	Age (years)	BMI (kg/m ²)	Combined with coronary heart disease	Combined with hypertension	Combined with diabetes	Hcy (μmol/L)
MACE Group	32	18/14	64.58±18.74	25.95±6.18	18 (56.25)	10 (31.25)	10 (31.25)	228.64±49.50
Nonmace group	84	44/40	62.91±18.20	24.89±6.37	30 (35.71)	26 (30.95)	21 (25.00)	147.34±31.29
x ² /t		0.139	0.438	0.808	1.575	0.001	0.262	10.538
P		0.709	0.662	0.421	0.210	0.982	0.609	<0.001
Group	n	hs-CRP (mg/L)	LVEF (%)	LVEDD (mm)	NT-pro-BNP (pg/mL) IG	FBP-7 (ng/mL)	CTRP12 (ng/mL)	
MACE Group	32	17.36±5.40	44.71±9.52	68.94±18.43	1895.18±320.62	78.49±23.35	1.87±0.64	
Nonmace group	84	10.27±3.56	55.41±11.84	61.54±15.14	1470.15±266.35	67.87±18.42	2.21±0.85	
x ² /t		8.240	-4.576	2.212	7.252	2.571	-2.05	
P		<0.001	0.001	0.029	<0.001	0.011	0.043	

Table IV Multivariate logistic regression analysis of the influencing factors of MACE in patients with CHF.

Factor	β	SE	Wald X2	P	OR	OR95%CI
NT-pro-BNP	0.848	0.307	7.630	0.006	2.335	1.279~4.262
IGFBP-7	0.953	0.365	6.820	0.009	2.594	1.268~5.305
CTRP12	-0.361	0.122	8.754	0.003	0.697	0.549~0.885

Comparison of general information, cardiac function indicators and levels of serum NT-pro-BNP, IGFBP-7, CTRP12, Hcy and hs-CRP between the MACE group and the non-MACE group

According to the occurrence of MACE within one year after discharge, Patients with CHF were split into two groups: 32 were MACE patients and 84 were non-MACE patients. Differences in age, sex, BMI, and combined coronary heart disease were not statistically significant, combined hypertension or combined diabetes between the MACE group and the non-MACE group ($P>0.05$). Compared with those in the non-MACE group, the levels of LVEF and serum CTRP12 in the MACE group decreased, the LVEDD increased, and there were significantly substantial ($P<0.05$) increases in serum Hcy, hs-CRP, NT-pro-BNP, and IGFBP-7 levels (Table III).

Determinants of MACEs in CHF patients were examined using multivariate logistic regression

The collinearity test revealed that hs-CRP and Hcy had a collinear relationship with CTRP12 (toler-

ance = 0.095, 0.075, and VIF = 10.53, 13.33), and LVEF and LVEDD had a collinear relationship with NT-pro-BNP (tolerance = 0.081, 0.064, and VIF = 12.35, 15). Thus, whether MACE occurred in CHF patients was the dependent variable for multivariate logistic regression analysis (occurrence = 1, nonoccurrence = 0), while the independent variables were solely NT-pro-BNP, IGFBP-7, and CTRP12 (all inputs had original values). The findings showed that MACEs in CHF patients were influenced by serum NT-pro-BNP, IGFBP-7, and CTRP12 levels ($P<0.05$) (Table IV).

Efficacy of serum NT-pro-BNP, IGFBP-7 and CTRP12 in predicting the occurrence of MACE in patients with CHF

The ROC curve was plotted according to whether MACE occurred in CHF patients (occurrence = 1, nonoccurrence = 0) as the state variable and serum NT-pro-BNP, IGFBP-7 and CTRP12 as the test variables. The areas under the curve (AUCs) of serum NT-pro-BNP, IGFBP-7, CTRP12 alone and the combination of the three for predicting MACE in patients with CHF were 0.862 (95% CI: 0.786–0.919), 0.805

Table V The efficacy of serum NT-pro-BNP, IGFBP-7 and CTRP12 in predicting MACE in patients with CHF.

Indicator	AUC	AUC95%CI	Optimal cutoff value	Sensitivity (%)	Specificity (%)	Youden Index	P
NT-pro-BNP	0.862	0.786~0.919	1693.98 pg/mL	75.00	84.52	0.595	<0.001
IGFBP-7	0.805	0.721~0.872	68.79 ng/mL	87.50	60.71	0.482	0.001
CTRP12	0.860	0.784~0.918	2.11 ng/mL	93.75	63.10	0.569	0.001
Three joint	0.961	0.908~0.988	–	90.62	91.67	0.823	<0.001

(95% CI: 0.721–0.872), 0.860 (95% CI: 0.784–0.918) and 0.961 (95% CI: 0.908–0.988), respectively. The AUCs of the three combined predictions were significantly greater than those of the individual predictions of NT-pro-BNP, IGFBP-7, and CTRP12 ($Z=3.050, 3.883, 3.218$, all $P<0.05$) (Table V).

Discussion

CHF is a type of myocardial injury caused by factors such as myocardial infarction. As the condition progresses, it may lead to ventricular pumping or overfilling, resulting in severe insufficiency of blood circulation in the arterial system (18–21). Moreover, the aetiology of CHF is complex, the course of the disease is long, and the prognosis is poor. Patients need to be hospitalised frequently and are prone to MACEs (22). Consequently, it is crucial to find biological markers that can reliably forecast a patient's prognosis.

NT-pro-BNP is the amino-terminal fragment cleaved during the secretion process of B-type brain natriuretic peptide (BNP) (23). Cardiomyocytes secrete it, and it enters the bloodstream through cellular stretching. Its secretion and release are closely related to ventricular dilation. Relevant studies (24–26) have shown that when cardiac function is impaired, NT-pro-BNP is synthesised and secreted in large quantities, and its level increases rapidly. As cardiac function improves, the serum NT-pro-BNP level in CHF patients also gradually increases (27). Moreover, ROC curve analysis revealed that the NT-pro-BNP level may have particular guiding significance for disease development and prognosis evaluation in CHF patients (28–30). Igfbp-7 is extensively expressed in various tissues and organs, including peripheral nerves, the digestive tract, and breast tissue, where it participates in regulating processes such as cell growth, proliferation, and apoptosis (31). Abnormal expression of IGFBP-7 can cause cell cycle arrest, tissue fibrosis, and promote the production of inflammatory cytokines. It is related to cardiac structure, diastolic function and the prognosis of CHF patients, and elevated levels of this protein increase the occurrence of MACEs (32). In addition, studies have shown that higher concentrations of IGFBP7 may lead to premature ageing of the myocardium, thereby causing myocardial fibrosis.

Patients with heart failure have serum IGFBP-7 levels that are noticeably higher than those of healthy people. The serum IGFBP-7 level in patients with CHF is significantly elevated and related to cardiac function grade (33). Additionally, the MACE group's blood IGFBP-7 level was noticeably higher than the non-MACE group's. The AUC of the serum IGFBP-7 level for predicting MACEs in patients with CHF was 0.805, indicating that the level of serum IGFBP-7 has good predictive value for MACEs in these patients (34). CTRP12 is distributed mainly in the adipose tissue and kidneys, and multiple factors influence its level in the body. CTRP12 has multiple physiological functions in the body, such as exerting anti-inflammatory effects and regulating glucose metabolism (35). Moreover, research has shown that CTRP12 can promote the process of vascular regeneration and alleviate the symptoms of myocardial fibrosis after myocardial infarction. Patients with severe CHD had lower serum CTRP12 levels than patients with moderate CHD, and as the severity of CHD increases, the amount steadily declines (36). The serum CTRP12 level in patients with CHF decreased, and as the cardiac function grade increased, the CTRP12 level gradually decreased (37).

In addition, this study revealed that in patients with CHF, the LVEF was significantly decreased, the LVEDD was increased, and the levels of serum Hcy and hs-CRP were significantly elevated, which were related to the cardiac function grade. Further verifying that LVEF, LVEDD, and the levels of serum Hcy and hs-CRP are related to the occurrence of CHF. However, the collinearity test revealed that hs-CRP and Hcy had a collinear relationship with CTRP12. LVEF, LVEDD and NT-pro-BNP have a collinear relationship (38). Therefore, hs-CRP, Hcy, LVEF and LVEDD were not included in the multivariate logistic regression analysis or ROC curve analysis. Hs-CRP and hcy have respective AUCs of 0.650 and 0.808 for forecasting a bad outcome. Additionally, the combined prediction of serum NT-pro-BNP, IGFBP-7, and CTRP12 for the occurrence of MACEs in congestive heart failure patients had an AUC of 0.961, which was significantly greater than the three individual AUCs, suggesting that the combination of the three factors has high efficacy in predicting the occurrence of MACEs in CHF patients.

Conclusion

Serum levels of IGFBP-7 and NT-pro-BNP rise in CHF patients, whereas the level of serum CTRP12 decreases. Moreover, NT-pro-BNP, IGFBP-7, and CTRP12 changed with functional classification. The combined detection of these three factors has greater efficacy in predicting MACEs in patients with CHF. This study will subsequently expand the sample size to further verify the predictive value of serum NT-pro-

BNP, IGFBP-7, and CTRP12 for the prognosis of CHF patients and conduct an in-depth analysis of their mechanism of action.

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.

References

- Dogheim GM, Amralla MT, Werida RH. The clinical significance of neopterin and NT-pro BNP in chronic heart failure: a systematic review. *Acta Cardiol* 2024; 79(6): 720–9. doi: 10.1080/00015385.2024.2371628. Epub 2024 Jun 27. PMID: 38934779
- Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. *ESC Heart Fail* 2022; 9(5): 3198–209. doi: 10.1002/ehf2.14019. Epub 2022 Jun 29. PMID: 35769032; PMCID: PMC9715818
- Zheng Y, Huang C, Zhang W, Shi Y, Chen F, Zhou J. Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure. *J Med Biochem* 2025; 44(3): 507–14. DOI: 10.5937/jomb0-54440.
- Militaru M, Lighezan DF, Tudoran C, Tudoran M, Militaru AG. Factors influencing the development and severity of cognitive decline in patients with chronic heart failure. *Medicina (Kaunas)* 2024; 60(11): 1859. doi: 10.3390/medicina60111859. PMID: 39597044; PMCID: PMC11596752
- Moscucci F, Sciomer S, Maffei S, Meloni A, Lospinuso I, Carnovale M, et al. Sex differences in repolarisation markers: telemonitoring for chronic heart failure patients. *J Clin Med* 2023; 12(14): 4714. doi: 10.3390/jcm12144714. PMID: 37510828; PMCID: PMC10381165
- Dattilo G, Bitto R, Correale M, Morabito C, Vaccaro V, Lattera G, et al. Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. *Minerva Cardiol Angiol* 2022; 70(5): 555–62. doi: 10.23736/S2724-5683.20.05494-8. Epub 2021 Apr 7. PMID: 33823573
- Chen W, Luo X, Li W, Li X, Wang Y, Zhang R, et al. Uncovering the active ingredients of Xinbao pill against chronic heart failure: a chemical profiling, pharmacokinetics and pharmacodynamics integrated study. *J Ethnopharmacol* 2025; 342: 119418. doi: 10.1016/j.jep.2025.119418. Epub 2025 Jan 27. PMID: 39880064
- Naser N, Kulić M, Jatić Z. Our experience with sacubitril/valsartan in chronic heart failure management—HFREF in the ambulatory setting. *Med Arch* 2022; 76(2): 101–7. doi: 10.5455/medarh.2022.76.101-107. PMID: 35774049; PMCID: PMC9233466
- Sharma S, Mathur D, Goswami S, Gupta MK, Bhardwaj P, Kumar P, et al. Prevalence of periodontitis in chronic heart failure patients and its relationship with NT-proBNP: a cross-sectional study. *Indian Heart J* 2025; 77(2): 110–3. doi: 10.1016/j.ihj.2025.03.004. Epub 2025 Mar 7. PMID: 40057232; PMCID: PMC12138112
- Feng ZF, Liu Y, Salvador JT, Ala MB, Nery MAC, Huang XY, Zhang L, Liu S, et al. Implementation and evaluation of hospital-to-home transitional care intervention in patients with chronic heart failure. *BMC Nurs* 2025; 24(1): 717. doi: 10.1186/s12912-025-03447-5. PMID: 40597265; PMCID: PMC12210740
- Pages N, Picard F, Barritault F, Amara W, Lafitte S, Maribas P, et al. Remote patient monitoring for chronic heart failure in France: when an innovative funding program (ETAPES) meets an innovative solution (Satelia® Cardio). *Digit Health* 2022; 8: 20552076221116774. doi: 10.1177/20552076221116774. PMID: 36034602; PMCID: PMC9403459
- Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. *Aging (Albany NY)* 2021; 13(8): 10833–52. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137
- Lin ZB, Teng ZH, Xu YR, Deng YS, Liang GL, Deng HY, et al. Predictive value of whole blood cell derived inflammatory markers in combination with NT-proBNP on the prognosis of patients with chronic heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi* 2025; 53(2): 143–50. Chinese. doi: 10.3760/cma.j.cn112148-20241211-00774. PMID: 39965849
- Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Dro d J, et al. IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. *JACC Heart Fail* 2023; 11(3): 291–304. doi: 10.1016/j.jchf.2022.09.004. Epub 2022 Nov 9. PMID: 36592046
- Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, et al. Immunomodulatory factor TIM3 of cytolytic active genes affected the survival and prognosis of lung adenocarcinoma patients by multi-omics analysis. *Bio-medicines* 2022; 10(9): 2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572

16. Wu L, Yang L, Qian X, Hu W, Wang S, Yan J. Mannan-decorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment. *J Funct Biomater* 2024; 15(8): 229. doi: 10.3390/jfb15080229. PMID: 39194667; PMCID: PMC11355305
17. Moltó-Balado P, Reverté-Villarroya S, Monclús-Arasa C, Balado-Albiol MT, Baset-Martínez S, Carot-Domenech J, et al. Heart failure and major adverse cardiovascular events in atrial fibrillation patients: a retrospective primary care cohort study. *Biomedicines* 2023; 11(7): 1825. doi: 10.3390/biomedicines11071825. PMID: 37509465; PMCID: PMC10376826
18. Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, et al. Multiple omics analysis of the role of RBM10 gene instability in immune regulation and drug sensitivity in patients with lung adenocarcinoma (LUAD). *Biomedicines* 2023; 11(7): 1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220
19. Du J, Yang L, Hao Z, Li H, Yang C, Wang X, et al. Development and validation of a nomogram for major adverse cardiovascular events after chronic total occlusion percutaneous coronary intervention for ischemic heart failure. *Catheter Cardiovasc Interv* 2024; 104(3): 451–61. doi: 10.1002/ccd.31139. Epub 2024 Jul 20. PMID: 39033330
20. Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, et al. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. *Lancet Diabetes Endocrinol* 2025; 13(4): 321–32. doi: 10.1016/S2213-8587(24)00362-0. Epub 2025 Feb 14. PMID: 39961315
21. Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, et al. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. *Anticancer Drugs* 2022; 33(1): e590–e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349
22. Kavousi S, Hosseinpour A, Bahmanzadegan Jahromi F, Attar A. Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomised controlled trials. *J Transl Med* 2024; 22(1): 786. doi: 10.1186/s12967-024-05352-y. PMID: 39174960; PMCID: PMC11342608
23. Le Gall L, Harambat J, Combe C, Philipps V, Proust-Lima C, Dussartre M, et al. Hemoglobin trajectories in chronic kidney disease and risk of major adverse cardiovascular events. *Nephrol Dial Transplant* 2024; 39(4): 669–82. doi: 10.1093/ndt/gfad235. PMID: 37935529
24. Desingu R, Kaore S, Kandelwal G, Balakrishnan S. Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalisation and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India. *Egypt Heart J* 2024; 76(1): 67. doi: 10.1186/s43044-024-00500-7. PMID: 38819505; PMCID: PMC11143102
25. Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, et al. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. *Anticancer Drugs* 2022; 33(9): 943–59. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295
26. Zhang L, Ou X, Lin J, Luo X, Zhou J, Zhou X, Zhao P, et al. Red blood cell membrane lipidomics: potential biomarkers detecting method for plasma volume overload and major adverse cardiovascular events in chronic heart failure patients. *Adv Sci (Weinh)* 2025; e02893. doi: 10.1002/adv.202502893. Epub ahead of print. PMID: 40548468
27. Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, et al. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. *Int J Bioprinting* 2024; 10(1): 1256. doi: 10.36922/ijb.1256
28. Wu L, Li X, Yan J. Commentary: machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. *Transl Oncol* 2024; 45: 101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241
29. Sulaiman S, Mohamed Khalafallah RA, Elbadri A, Abuelgasim Mohamedsalih TM, Mahmoud A, Mohamed Salih Abdelrahman MA, et al. Serum Galectin-3 and risk stratification in chronic heart failure: a systematic review of mortality outcomes. *Cureus* 2025; 17(6): e86959. doi: 10.7759/cureus.86959. PMID: 40734851; PMCID: PMC12306356
30. Traub J, Schuhmann MK, Sell R, Frantz S, Störk S, Stoll G, et al. S100B serum levels in chronic heart failure patients: a multifaceted biomarker linking cardiac and cognitive dysfunction. *Int J Mol Sci* 2024; 25(16): 9094. doi: 10.3390/ijms25169094. PMID: 39201780; PMCID: PMC11354705
31. Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. *Vaccines (Basel)* 2024; 12(2): 186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594
32. Armentaro G, Condoleo V, Pastura CA, Grasso M, Frasca A, Martire D, et al. Prognostic role of serum albumin levels in patients with chronic heart failure. *Intern Emerg Med* 2024; 19(5): 1323–33. doi: 10.1007/s11739-024-03612-9. Epub 2024 May 22. PMID: 38776047; PMCID: PMC11364577
33. Zheng YY, Wu TT, Hou XG, Yang HT, Yang Y, Xiu WJ, et al. Serum a-1 antitrypsin as a novel biomarker in chronic heart failure. *ESC Heart Fail* 2023; 10(5): 2865–74. doi: 10.1002/ehf2.14451. Epub 2023 Jul 7. PMID: 37417425; PMCID: PMC10567649
34. Ni F, Xiang Y. Correlation between serum cystatin C and lipid level in patients with chronic heart failure. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2023; 48(1): 34–9. English, Chinese. doi: 10.11817/j.issn.1672-7347.2023.220025. PMID: 36935175; PMCID: PMC10930551
35. Xie L, Zhou Z, Chen HX, Yan XY, Ye JQ, Jiang Y, Zhou L, et al. Correlations between serum laminin level and

- severity of heart failure in patients with chronic heart failure. *Front Cardiovasc Med* 2023; 10: 1089304. doi: 10.3389/fcvm.2023.1089304. PMID: 37008313; PMCID: PMC10060624
36. Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, et al. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. *Heliyon* 2024; 10(7): e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709
37. Amaechi UM, Aiwuyo HO, Ewelukwa C, Ilerhunmwuwa N, Osarenkhoe JO, et al. Assessing iron status in chronic heart failure patients by using serum ferritin and transferrin saturation levels: a cross-sectional descriptive study. *Cureus* 2023; 15(5): e39425. doi: 10.7759/cureus.39425. PMID: 37362450; PMCID: PMC10288524
38. Matin SS, Shidfar F, Naderi N, Amin A, Hosseini-Baharanchi FS, Dehnad A. The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomised, triple-blind, controlled trial. *Sci Rep* 2024; 14(1): 19120. doi: 10.1038/s41598-024-69560-8. PMID: 39155305; PMCID: PMC11330970

Received: December 21, 2025

Accepted: January 23, 2026